-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Immunoglobulin (Ig) replacement therapy is a life-saving therapy for primary antibody deficiency
.
The introduction of subcutaneous immunoglobulin (SCIg) has greatly improved the quality of life of patients compared to traditional intravenous administration
This study aimed to increase knowledge on the anti-inflammatory and immunomodulatory effects of SCIg in the treatment of myositis
.
To this end, the efficacy of 20% human SCIg therapy (20% SCIg, Hizentra®, CSL Behring) was long-term assessed in PM/DM patients cared for at our center
Results support the beneficial effect and tolerability of 20% SCIg long-term treatment in PM/DM patients, reporting creatine kinase levels, muscle strength, skin condition, dysphagia, disease activity (MITAX score), and disability (HAQ-DI score) Significant improvement
.
No systemic reactions were reported in any of the patients
This study suggests that 20% SCIg in the treatment of PM/DM is a safe and feasible treatment, an effective alternative to IVIg, and has important advantages in improving the quality of life of patients
Source: Danieli MG, Verga JU, Mezzanotte C, et al.
leave a message here